| (R)-Hydroxychloroquine |
|
|
|
|
|
|
|
|
|
| (R)-Hydroxychloroquine phosphate |
|
|
|
|
|
|
|
|
|
| (R)-SARM1-IN-5 |
|
|
|
|
|
|
|
|
97.68% |
| (Rac)-VB-201 |
|
|
|
|
|
|
|
|
|
| (S)-Hydroxychloroquine |
|
|
|
|
|
|
|
|
|
| (S)-Hydroxychloroquine sulfate |
|
|
|
|
|
|
|
|
|
| (S,S)-SARM1-IN-9 |
|
|
|
|
|
|
|
|
99.67% |
| (±)-Naringenin |
|
|
|
|
|
|
|
|
99.83% |
| 1V209 |
|
|
|
|
|
|
|
|
99.67% |
| 1Z105 |
|
|
|
|
|
|
|
|
|
| 3A-MPLA ammonium |
|
|
|
|
|
|
|
|
|
| 3D-Monophosphoryl Lipid (12,16) |
|
|
|
|
|
|
|
|
|
| 3D-Monophosphoryl Lipid (12,16) free acid |
|
|
|
|
|
|
|
|
|
| 3D-Monophosphoryl Lipid (12,16) triethylamine |
|
|
|
|
|
|
|
|
|
| 3D-Monophosphoryl Lipid (14) |
|
|
|
|
|
|
|
|
|
| 3D-Monophosphoryl Lipid (14) ammonium |
|
|
|
|
|
|
|
|
|
| 3D-Monophosphoryl Lipid (14) triethylamine |
|
|
|
|
|
|
|
|
|
| 3D-Monophosphoryl Lipid A-5 |
|
|
|
|
|
|
|
|
99.60% |
| 3D-Monophosphoryl Lipid A-5 free acid |
|
|
|
|
|
|
|
|
|
| 3D-Monophosphoryl Lipid A-5 triethylamine |
|
|
|
|
|
|
|
|
|
| 3M-011 |
|
|
|
|
|
|
|
|
|
| 4,7-Dimethoxy-5-methyl-1,3-benzodioxole |
|
|
|
|
|
|
|
|
|
| 4-Methoxylonchocarpin |
|
|
|
|
|
|
|
|
98.0% |
| 4-Octylphenol |
|
|
|
|
|
|
|
|
|
| 4A-MPLA ammonium |
|
|
|
|
|
|
|
|
|
| 5-Chloroisoquinoline |
|
|
|
|
|
|
|
|
|
| DSRM-3716 |
|
|
|
|
|
|
|
|
99.91% |
| Juglone |
|
|
|
|
|
|
|
|
99.77% |
| 6-Methoxyflavone |
|
|
|
|
|
|
|
|
99.73% |
| 7α-Hydroxycholesterol |
|
|
|
|
|
|
|
|
99.99% |
| 8-Mercaptoguanosine |
|
|
|
|
|
|
|
|
98.0% |
| a15:0-i15:0 PE |
|
|
|
|
|
|
|
|
|
| ABB071 |
|
|
|
|
|
|
|
|
|
| ABR-238901 |
|
|
|
|
|
|
|
|
98.92% |
| Afimetoran |
|
|
|
|
|
|
|
|
99.37% |
| Agatolimod |
|
|
|
|
|
|
|
|
98.84% |
| Agatolimod sodium |
|
|
|
|
|
|
|
|
99.13% |
| Aluminum hydroxide adjuvant aluminum : 4~6 mg/mL |
|
|
|
|
|
|
|
|
|
| AN-3485 |
|
|
|
|
|
|
|
|
97.38% |
| AN-3485 hydrochloride |
|
|
|
|
|
|
|
|
|
| Anti-CD14 Antibody (UCHM-1) |
|
|
|
|
|
|
|
|
|
| Anti-Dectin-1 Antibody (2M24) |
|
|
|
|
|
|
|
|
97.29% |
| Anti-inflammatory agent 97 |
|
|
|
|
|
|
|
|
|
| Anti-TLR3/CD283 Antibody (CNTO5429) |
|
|
|
|
|
|
|
|
|
| Anti-TLR7 Antibody |
|
|
|
|
|
|
|
|
≥99.0% |
| Antibacterial agent 284 |
|
|
|
|
|
|
|
|
|
| Antifungal agent 123 |
|
|
|
|
|
|
|
|
|
| Antitumor agent-185 |
|
|
|
|
|
|
|
|
|
| APG-7 |
|
|
|
|
|
|
|
|
|
| Arabinoxylan (Medium viscosity) |
|
|
|
|
|
|
|
|
95% |
| ArMan |
|
|
|
|
|
|
|
|
|
| Artemisinin B |
|
|
|
|
|
|
|
|
|
| AT791 |
|
|
|
|
|
|
|
|
98.12% |
| AXC-715 hydrochloride |
|
|
|
|
|
|
|
|
99.89% |
| AXC-715 trihydrochloride |
|
|
|
|
|
|
|
|
99.76% |
| AXC-879 |
|
|
|
|
|
|
|
|
|
| AYK004 |
|
|
|
|
|
|
|
|
|
| AYK004-B1 |
|
|
|
|
|
|
|
|
|
| AYK004-C1 |
|
|
|
|
|
|
|
|
|
| AYK005 |
|
|
|
|
|
|
|
|
|
| AZ12441970 |
|
|
|
|
|
|
|
|
|
| AZD8848 |
|
|
|
|
|
|
|
|
99.14% |
| Bazlitoran |
|
|
|
|
|
|
|
|
95.30% |
| Bazlitoran sodium |
|
|
|
|
|
|
|
|
95.30% |
| BBIQ |
|
|
|
|
|
|
|
|
99.81% |
| BBIQ (GMP) |
|
|
|
|
|
|
|
|
|
| Benzylmethyl ether |
|
|
|
|
|
|
|
|
98.70% |
| BI1543673 |
|
|
|
|
|
|
|
|
|
| BIM-46174 |
|
|
|
|
|
|
|
|
|
| Biotin-labeled agatolimod sodium |
|
|
|
|
|
|
|
|
95.21% |
| Biotin-labeled ODN 1018 sodium |
|
|
|
|
|
|
|
|
|
| Biotin-labeled ODN 1585 sodium |
|
|
|
|
|
|
|
|
|
| Biotin-labeled ODN 1668 sodium |
|
|
|
|
|
|
|
|
|
| Biotin-labeled ODN 1826 sodium |
|
|
|
|
|
|
|
|
99.39% |
| Biotin-labeled ODN 2088 sodium |
|
|
|
|
|
|
|
|
|
| Biotin-labeled ODN 2216 sodium |
|
|
|
|
|
|
|
|
91.06% |
| Biotin-labeled ODN 2395 sodium |
|
|
|
|
|
|
|
|
93.84% |
| Biotin-labeled ODN TTAGGG sodium |
|
|
|
|
|
|
|
|
|
| BMS-986126 |
|
|
|
|
|
|
|
|
|
| BMS905 |
|
|
|
|
|
|
|
|
98.25% |
| BNT411 |
|
|
|
|
|
|
|
|
99.01% |
| Bropirimine |
|
|
|
|
|
|
|
|
99.94% |
| BSF2 |
|
|
|
|
|
|
|
|
|
| BuChE-IN-23 |
|
|
|
|
|
|
|
|
|
| BXY-14 |
|
|
|
|
|
|
|
|
|
| C12-TLRa |
|
|
|
|
|
|
|
|
99.71% |
| C29 |
|
|
|
|
|
|
|
|
98.0% |
| Cathelicidin-PY |
|
|
|
|
|
|
|
|
|
| Cavrotolimod |
|
|
|
|
|
|
|
|
|
| Cavrotolimod sodium |
|
|
|
|
|
|
|
|
|
| Cavrotolimod sodium scrambled negative control |
|
|
|
|
|
|
|
|
|
| CAY10614 |
|
|
|
|
|
|
|
|
98.87% |
| CCL-34 |
|
|
|
|
|
|
|
|
|
| Chlojaponilactone B |
|
|
|
|
|
|
|
|
98.0% |
| Chuanbeinone |
|
|
|
|
|
|
|
|
|
| CIAC101 |
|
|
|
|
|
|
|
|
|
| CL075 |
|
|
|
|
|
|
|
|
99.18% |
| CL097 |
|
|
|
|
|
|
|
|
99.90% |
| CL097 hydrochloride |
|
|
|
|
|
|
|
|
99.96% |
| CL264 |
|
|
|
|
|
|
|
|
98.05% |
| CNTO-3157 |
|
|
|
|
|
|
|
|
|
| Cobitolimod |
|
|
|
|
|
|
|
|
97.14% |
| Cobitolimod sodium |
|
|
|
|
|
|
|
|
|
| Cobitolimod sodium scrambled negative control |
|
|
|
|
|
|
|
|
|
| Complete Freund's adjuvant (CFA, 1 mg/ml) |
|
|
|
|
|
|
|
|
|
| CpG ODN 10101 |
|
|
|
|
|
|
|
|
99.44% |
| CpG ODN 10101 sodium |
|
|
|
|
|
|
|
|
98.84% |
| CPG-52364 |
|
|
|
|
|
|
|
|
99.20% |
| CpG-ODN c41 |
|
|
|
|
|
|
|
|
|
| CpG-ODN c41 sodium |
|
|
|
|
|
|
|
|
|
| Creatine ethyl ester |
|
|
|
|
|
|
|
|
|
| CRX 527 |
|
|
|
|
|
|
|
|
|
| CRX-526 |
|
|
|
|
|
|
|
|
|
| CU-115 |
|
|
|
|
|
|
|
|
99.63% |
| CU-CPD107 |
|
|
|
|
|
|
|
|
98.07% |
| CU-CPT 4a |
|
|
|
|
|
|
|
|
99.50% |
| CU-CPT-8m |
|
|
|
|
|
|
|
|
99.98% |
| CU-CPT-9a |
|
|
|
|
|
|
|
|
99.74% |
| CU-CPT17e |
|
|
|
|
|
|
|
|
98.67% |
| CU-CPT22 |
|
|
|
|
|
|
|
|
98.08% |
| CU-CPT9b |
|
|
|
|
|
|
|
|
98.26% |
| CU-T12-9 |
|
|
|
|
|
|
|
|
99.96% |
| Curdlan |
|
|
|
|
|
|
|
|
98.5% |
| D-Allose |
|
|
|
|
|
|
|
|
99.85% |
| D-Glucuronic acid |
|
|
|
|
|
|
|
|
98.0% |
| D-Glucuronic acid sodium salt monohydrate |
|
|
|
|
|
|
|
|
98.0% |
| D18 |
|
|
|
|
|
|
|
|
98.14% |
| DB-3-291 |
|
|
|
|
|
|
|
|
99.08% |
| Defoslimod |
|
|
|
|
|
|
|
|
|
| Desethyl chloroquine |
|
|
|
|
|
|
|
|
|
| Desethyl chloroquine diphosphate |
|
|
|
|
|
|
|
|
99.72% |
| Desethyl chloroquine-d4 |
|
|
|
|
|
|
|
|
|
| Desethyl chloroquine-d5 |
|
|
|
|
|
|
|
|
|
| Diprovocim |
|
|
|
|
|
|
|
|
98.82% |
| Diprovocim-X |
|
|
|
|
|
|
|
|
98.64% |
| DS-7011a |
|
|
|
|
|
|
|
|
|
| DSP30 |
|
|
|
|
|
|
|
|
95.27% |
| DSR-6434 |
|
|
|
|
|
|
|
|
99.32% |
| E-5531 |
|
|
|
|
|
|
|
|
|
| E104 |
|
|
|
|
|
|
|
|
99.38% |
| E6446 |
|
|
|
|
|
|
|
|
98.78% |
| E6446 dihydrochloride |
|
|
|
|
|
|
|
|
99.96% |
| Egg oil |
|
|
|
|
|
|
|
|
99.0% |
| ENDO12 |
|
|
|
|
|
|
|
|
|
| Enpatoran |
|
|
|
|
|
|
|
|
99.80% |
| Enpatoran hydrochloride |
|
|
|
|
|
|
|
|
99.42% |
| Ergosta-7,22-dien-3-one |
|
|
|
|
|
|
|
|
96% |
| Ethyl glucuronide |
|
|
|
|
|
|
|
|
99.22% |
| Ethyl glucuronide-d5 |
|
|
|
|
|
|
|
|
97.0% |
| ETI41 |
|
|
|
|
|
|
|
|
|
| ETI60 |
|
|
|
|
|
|
|
|
99.51% |
| FAM-labeled ODN 1826 sodium |
|
|
|
|
|
|
|
|
98.03% |
| FGT-4 |
|
|
|
|
|
|
|
|
|
| FITC-labeled agatolimod sodium |
|
|
|
|
|
|
|
|
|
| FITC-labeled ODN 1018 sodium |
|
|
|
|
|
|
|
|
98.71% |
| FITC-labeled ODN 1585 sodium |
|
|
|
|
|
|
|
|
|
| FITC-labeled ODN 1668 sodium |
|
|
|
|
|
|
|
|
|
| FITC-labeled ODN 1826 sodium |
|
|
|
|
|
|
|
|
96.06% |
| FITC-labeled ODN 2088 sodium |
|
|
|
|
|
|
|
|
|
| FITC-labeled ODN 2216 sodium |
|
|
|
|
|
|
|
|
93.96% |
| FITC-labeled ODN 2395 sodium |
|
|
|
|
|
|
|
|
98.89% |
| FITC-labeled ODN TTAGGG sodium |
|
|
|
|
|
|
|
|
|
| Flagellin from S. typhimurium |
|
|
|
|
|
|
|
|
95% |
| FP-18 disodium |
|
|
|
|
|
|
|
|
|
| FP-20 sodium |
|
|
|
|
|
|
|
|
|
| FP20Rha |
|
|
|
|
|
|
|
|
|
| FSL-1 |
|
|
|
|
|
|
|
|
99.22% |
| FSL-1 TFA |
|
|
|
|
|
|
|
|
99.81% |
| Ganglioside GD1a |
|
|
|
|
|
|
|
|
|
| Ganglioside GT1b (bovine) trisodium |
|
|
|
|
|
|
|
|
|
| Ganoderic acid K |
|
|
|
|
|
|
|
|
|
| GAP214 |
|
|
|
|
|
|
|
|
|
| Gardiquimod |
|
|
|
|
|
|
|
|
99.91% |
| Gardiquimod diTFA |
|
|
|
|
|
|
|
|
99.0% |
| Gardiquimod hydrochloride |
|
|
|
|
|
|
|
|
|
| GlcNAc-MurNAc |
|
|
|
|
|
|
|
|
95.37% |
| GNE-5152 |
|
|
|
|
|
|
|
|
|
| GNKG168 |
|
|
|
|
|
|
|
|
|
| GNKG168 sodium |
|
|
|
|
|
|
|
|
|
| GSK1795091 |
|
|
|
|
|
|
|
|
94.48% |
| GSK2245035 |
|
|
|
|
|
|
|
|
99.79% |
| GSK2245035 maleate |
|
|
|
|
|
|
|
|
|
| Guignardone L |
|
|
|
|
|
|
|
|
|
| Guluronic acid sodium |
|
|
|
|
|
|
|
|
98.0% |
| Guretolimod |
|
|
|
|
|
|
|
|
|
| Guretolimod hydrochloride |
|
|
|
|
|
|
|
|
98.67% |
| HCN-IN-1 |
|
|
|
|
|
|
|
|
|
| HE-S2 |
|
|
|
|
|
|
|
|
|
| Hecubine |
|
|
|
|
|
|
|
|
|
| HMGB1-IN-3 |
|
|
|
|
|
|
|
|
|
| HS101 |
|
|
|
|
|
|
|
|
|
| HS105 |
|
|
|
|
|
|
|
|
|
| HS201 |
|
|
|
|
|
|
|
|
|
| HVF18-a3-d |
|
|
|
|
|
|
|
|
|
| IAV-IN-5 |
|
|
|
|
|
|
|
|
|
| IAXO-101 iodide |
|
|
|
|
|
|
|
|
|
| IAXO-102 |
|
|
|
|
|
|
|
|
98.0% |
| IMG-2005 |
|
|
|
|
|
|
|
|
|
| Imiquimod dihydrochloride |
|
|
|
|
|
|
|
|
|
| INI-4001 |
|
|
|
|
|
|
|
|
|
| Inotodiol |
|
|
|
|
|
|
|
|
98.29% |
| IPH33 |
|
|
|
|
|
|
|
|
|
| IRF5-CPP5 |
|
|
|
|
|
|
|
|
99.23% |
| IRF5-IN-1 |
|
|
|
|
|
|
|
|
99.91% |
| Isatoribine |
|
|
|
|
|
|
|
|
|
| ISIS 1082 sodium scrambled negative control |
|
|
|
|
|
|
|
|
|
| JAK1-IN-16 |
|
|
|
|
|
|
|
|
|
| JM-9 |
|
|
|
|
|
|
|
|
|
| Kaempferol 3-O-gentiobioside |
|
|
|
|
|
|
|
|
99.88% |
| Kaempferol 3-O-sophoroside |
|
|
|
|
|
|
|
|
99.41% |
| KBD4466 |
|
|
|
|
|
|
|
|
|
| Kdo2-Lipid A ammonium |
|
|
|
|
|
|
|
|
95.2% |
| KM91104 |
|
|
|
|
|
|
|
|
98.06% |
| L07-2 |
|
|
|
|
|
|
|
|
99.83% |
| L48H37 |
|
|
|
|
|
|
|
|
97.13% |
| L6H21 |
|
|
|
|
|
|
|
|
99.19% |
| LHC-165 |
|
|
|
|
|
|
|
|
98.0% |
| Ligusticum cycloprolactam |
|
|
|
|
|
|
|
|
|
| Lipopolysaccharides, from Salmonella typhosa |
|
|
|
|
|
|
|
|
|
| Liposomal adjuvant (M103) |
|
|
|
|
|
|
|
|
|
| Litenimod |
|
|
|
|
|
|
|
|
|
| Litenimod sodium |
|
|
|
|
|
|
|
|
|
| LM9 |
|
|
|
|
|
|
|
|
|
| Loxoribine |
|
|
|
|
|
|
|
|
99.94% |
| LYRM03 |
|
|
|
|
|
|
|
|
|
| Lytx-Pa2a |
|
|
|
|
|
|
|
|
|
| m-AM-BBIQ |
|
|
|
|
|
|
|
|
|
| M101 |
|
|
|
|
|
|
|
|
|
| M199 |
|
|
|
|
|
|
|
|
98.55% |
| M62812 |
|
|
|
|
|
|
|
|
99.86% |
| M62812 free base |
|
|
|
|
|
|
|
|
|
| M903 |
|
|
|
|
|
|
|
|
|
| Macrophage-activating lipopeptide 2 |
|
|
|
|
|
|
|
|
|
| Macrophage-activating lipopeptide 2 TFA |
|
|
|
|
|
|
|
|
99.83% |
| Magnesium citrate |
|
|
|
|
|
|
|
|
98.0% |
| Mal-TLR7 agonist 32 |
|
|
|
|
|
|
|
|
|
| MAPK-IN-1 |
|
|
|
|
|
|
|
|
98.11% |
| Mc-Asn-Asn-E104 |
|
|
|
|
|
|
|
|
|
| MC-Val-Cit-PAB-Amide-TLR7 agonist 4 |
|
|
|
|
|
|
|
|
|
| MC-Val-Cit-PAB-Amide-TLR7 agonist 4 formic |
|
|
|
|
|
|
|
|
97.70% |
| MD2-IN-1 |
|
|
|
|
|
|
|
|
99.88% |
| MD2-TLR4-IN-1 |
|
|
|
|
|
|
|
|
98.16% |
| Methylchloroisothiazolinone |
|
|
|
|
|
|
|
|
|
| MMG-11 |
|
|
|
|
|
|
|
|
99.24% |
| MMG-11 quarterhydrate |
|
|
|
|
|
|
|
|
98.74% |
| Monophosphoryl lipid A |
|
|
|
|
|
|
|
|
99.87% |
| Monophosphoryl lipid A free acid |
|
|
|
|
|
|
|
|
|
| Monophosphoryl lipid A Triethylamine |
|
|
|
|
|
|
|
|
|
| Monophosphoryl Lipid A-12 |
|
|
|
|
|
|
|
|
99% |
| Monophosphoryl Lipid A-12 triethylamine |
|
|
|
|
|
|
|
|
|
| Mosedipimod |
|
|
|
|
|
|
|
|
|
| Motolimod |
|
|
|
|
|
|
|
|
98.10% |
| MTT5 |
|
|
|
|
|
|
|
|
98.49% |
| MTvkPABC-P5 |
|
|
|
|
|
|
|
|
|
| MTvkPABC-P5 TFA |
|
|
|
|
|
|
|
|
98.78% |
| Mumefural |
|
|
|
|
|
|
|
|
95.17% |
| MyD88-IN-3 |
|
|
|
|
|
|
|
|
99.33% |
| N-(p-Coumaroyl) Serotonin |
|
|
|
|
|
|
|
|
99.03% |
| N-(p-Coumaroyl) Serotonin (Standard) |
|
|
|
|
|
|
|
|
|
| N-Palmitoyl-D-glucosamine |
|
|
|
|
|
|
|
|
|
| NAB815 |
|
|
|
|
|
|
|
|
|
| Nalmefene |
|
|
|
|
|
|
|
|
99.94% |
| Nalmefene Sulfate-d3 |
|
|
|
|
|
|
|
|
|
| NB-3 |
|
|
|
|
|
|
|
|
99.89% |
| NB-7 |
|
|
|
|
|
|
|
|
99.82% |
| NCI126224 |
|
|
|
|
|
|
|
|
99.77% |
| NecroX-7 |
|
|
|
|
|
|
|
|
99.69% |
| Nelitolimod |
|
|
|
|
|
|
|
|
|
| Nelitolimod sodium |
|
|
|
|
|
|
|
|
|
| Neoseptin 3 |
|
|
|
|
|
|
|
|
99.21% |
| NF-κB-IN-14 |
|
|
|
|
|
|
|
|
|
| NGI-235 |
|
|
|
|
|
|
|
|
99.70% |
| NOD2/TLR4 agonist-1 |
|
|
|
|
|
|
|
|
|
| Odetiglucan |
|
|
|
|
|
|
|
|
|
| ODN 1018 |
|
|
|
|
|
|
|
|
99.28% |
| ODN 1018 sodium |
|
|
|
|
|
|
|
|
97.49% |
| ODN 1668 |
|
|
|
|
|
|
|
|
99.03% |
| ODN 1668 sodium |
|
|
|
|
|
|
|
|
98.79% |
| ODN 1826 |
|
|
|
|
|
|
|
|
99.51% |
| ODN 1826 sodium |
|
|
|
|
|
|
|
|
99.51% |
| ODN 1982 |
|
|
|
|
|
|
|
|
|
| ODN 1982 sodium |
|
|
|
|
|
|
|
|
99.04% |
| ODN 2007 |
|
|
|
|
|
|
|
|
97.86% |
| ODN 2007 sodium |
|
|
|
|
|
|
|
|
99.69% |
| ODN 20844 |
|
|
|
|
|
|
|
|
96.14% |
| ODN 20844 sodium |
|
|
|
|
|
|
|
|
95.22% |
| ODN 2088 |
|
|
|
|
|
|
|
|
98.82% |
| ODN 2088 sodium |
|
|
|
|
|
|
|
|
98.82% |
| ODN 21158 |
|
|
|
|
|
|
|
|
98.16% |
| ODN 21158 sodium |
|
|
|
|
|
|
|
|
98.16% |
| ODN 21595 |
|
|
|
|
|
|
|
|
|
| ODN 21595 sodium |
|
|
|
|
|
|
|
|
|
| ODN 2216 |
|
|
|
|
|
|
|
|
98.57% |
| ODN 2216 sodium |
|
|
|
|
|
|
|
|
98.57% |
| ODN 2336 |
|
|
|
|
|
|
|
|
|
| ODN 2336 sodium |
|
|
|
|
|
|
|
|
97.80% |
| ODN 2395 |
|
|
|
|
|
|
|
|
98.20% |
| ODN 2395 sodium |
|
|
|
|
|
|
|
|
98.20% |
| ODN 24888 |
|
|
|
|
|
|
|
|
|
| ODN 24888 sodium |
|
|
|
|
|
|
|
|
98.70% |
| ODN 24987 |
|
|
|
|
|
|
|
|
|
| ODN 24987 sodium |
|
|
|
|
|
|
|
|
99.08% |
| ODN 24991 |
|
|
|
|
|
|
|
|
99.64% |
| ODN 24991 sodium |
|
|
|
|
|
|
|
|
99.64% |
| ODN 4084-F |
|
|
|
|
|
|
|
|
91.29% |
| ODN 4084-F sodium |
|
|
|
|
|
|
|
|
91.29% |
| ODN 5328 |
|
|
|
|
|
|
|
|
|
| ODN 5328 sodium |
|
|
|
|
|
|
|
|
97.15% |
| ODN D-SL01 |
|
|
|
|
|
|
|
|
94.32% |
| ODN D-SL01 sodium |
|
|
|
|
|
|
|
|
94.32% |
| ODN INH 18 |
|
|
|
|
|
|
|
|
|
| ODN INH 18 sodium |
|
|
|
|
|
|
|
|
97.03% |
| ODN INH 18 triethylamine |
|
|
|
|
|
|
|
|
|
| ODN INH-1 |
|
|
|
|
|
|
|
|
|
| ODN INH-1 sodium |
|
|
|
|
|
|
|
|
|
| ODN M326 |
|
|
|
|
|
|
|
|
|
| ODN M326 sodium |
|
|
|
|
|
|
|
|
|
| ODN M362 |
|
|
|
|
|
|
|
|
96.01% |
| ODN M362 sodium |
|
|
|
|
|
|
|
|
97.02% |
| ODN TTAGGG |
|
|
|
|
|
|
|
|
93.96% |
| ODN TTAGGG sodium |
|
|
|
|
|
|
|
|
93.80% |
| ORN 02 |
|
|
|
|
|
|
|
|
|
| ORN 02 sodium |
|
|
|
|
|
|
|
|
|
| ORN 06 |
|
|
|
|
|
|
|
|
|
| ORN 06 sodium |
|
|
|
|
|
|
|
|
95.05% |
| Oxidized low density lipoprotein (Human) |
|
|
|
|
|
|
|
|
|
| P53/TLR2 modulator-1 |
|
|
|
|
|
|
|
|
|
| Pam2CSK4 |
|
|
|
|
|
|
|
|
|
| Pam2CSK4 TFA |
|
|
|
|
|
|
|
|
99.46% |
| Pam2Cys |
|
|
|
|
|
|
|
|
99.82% |
| Pam3CSK4 |
|
|
|
|
|
|
|
|
|
| Pam3CSK4 TFA |
|
|
|
|
|
|
|
|
99.89% |
| Pam3CSK4-Biotin |
|
|
|
|
|
|
|
|
|
| Pam3CSK4-Biotin TFA |
|
|
|
|
|
|
|
|
98.02% |
| Pamidronic acid sodium |
|
|
|
|
|
|
|
|
|
| Pap12-6-10 |
|
|
|
|
|
|
|
|
|
| Papiliocin |
|
|
|
|
|
|
|
|
|
| Paridiprubart |
|
|
|
|
|
|
|
|
≥95.0% |
| Pellitorine |
|
|
|
|
|
|
|
|
98.30% |
| Pepinh-TRIF TFA |
|
|
|
|
|
|
|
|
99.79% |
| Pertuzumab zuvotolimod |
|
|
|
|
|
|
|
|
98.64% |
| PF-4878691 |
|
|
|
|
|
|
|
|
99.19% |
| Phoenixin-14 |
|
|
|
|
|
|
|
|
99.28% |
| Phoenixin-14 TFA |
|
|
|
|
|
|
|
|
|
| Pig TRIM56 mRNA |
|
|
|
|
|
|
|
|
|
| Pinus pinaster bark extract |
|
|
|
|
|
|
|
|
95.79% |
| Polvitolimod |
|
|
|
|
|
|
|
|
|
| Poly (I:C):Kanamycin (1:1) |
|
|
|
|
|
|
|
|
48.60% |
| Poly (I:C):Kanamycin (1:1) sodium |
|
|
|
|
|
|
|
|
99.0% |
| Poly(C) |
|
|
|
|
|
|
|
|
|
| Poly(U) |
|
|
|
|
|
|
|
|
|
| Polyinosinic acid |
|
|
|
|
|
|
|
|
|
| Polyinosinic acid sodium |
|
|
|
|
|
|
|
|
91.5% |
| Polyinosinic-polycytidylic acid |
|
|
|
|
|
|
|
|
99.40% |
| Polyinosinic-polycytidylic acid (GMP Like) |
|
|
|
|
|
|
|
|
90.5% |
| Polyinosinic-polycytidylic acid sodium |
|
|
|
|
|
|
|
|
99.4% |
| Poseltinib |
|
|
|
|
|
|
|
|
98.11% |
| PROTAC IRAK4 degrader-13 |
|
|
|
|
|
|
|
|
99.47% |
| PTD-N5-1 |
|
|
|
|
|
|
|
|
|
| PTPRO-IN-1 |
|
|
|
|
|
|
|
|
|
| PVP-037 |
|
|
|
|
|
|
|
|
|
| PVP-037.2 |
|
|
|
|
|
|
|
|
98.40% |
| QS-21 |
|
|
|
|
|
|
|
|
98.93% |
| R1-ICR-5 |
|
|
|
|
|
|
|
|
98.73% |
| Rabeximod |
|
|
|
|
|
|
|
|
|
| RDR 02308 |
|
|
|
|
|
|
|
|
98.0% |
| Resiquimod |
|
|
|
|
|
|
|
|
|
| Retrocyclin-101 |
|
|
|
|
|
|
|
|
|
| Retrocyclin-101 TFA |
|
|
|
|
|
|
|
|
96.69% |
| RKH |
|
|
|
|
|
|
|
|
|
| RKH acetate |
|
|
|
|
|
|
|
|
99.79% |
| RS 09 |
|
|
|
|
|
|
|
|
99.84% |
| RS 09 TFA |
|
|
|
|
|
|
|
|
99.87% |
| Ruzotolimod |
|
|
|
|
|
|
|
|
99.92% |
| Saquinavir-13C6 |
|
|
|
|
|
|
|
|
|
| SARM1-IN-10 |
|
|
|
|
|
|
|
|
|
| SARM1-IN-2 |
|
|
|
|
|
|
|
|
99.97% |
| SARM1-IN-3 |
|
|
|
|
|
|
|
|
|
| SARM1-IN-4 |
|
|
|
|
|
|
|
|
|
| SARM1-IN-5 |
|
|
|
|
|
|
|
|
99.93% |
| SARM1-IN-6 |
|
|
|
|
|
|
|
|
|
| SARM1-IN-8 |
|
|
|
|
|
|
|
|
|
| SARM1-IN-9 |
|
|
|
|
|
|
|
|
98.42% |
| SBT8230 Antibody |
|
|
|
|
|
|
|
|
|
| Selgantolimod |
|
|
|
|
|
|
|
|
98.18% |
| Sitmutolimod |
|
|
|
|
|
|
|
|
|
| Sitmutolimod sodium |
|
|
|
|
|
|
|
|
|
| SjDX5-271 |
|
|
|
|
|
|
|
|
98.90% |
| SjDX5-271v |
|
|
|
|
|
|
|
|
|
| SjDX5-53 |
|
|
|
|
|
|
|
|
|
| SjDX5-53 control peptide |
|
|
|
|
|
|
|
|
|
| SM-276001 |
|
|
|
|
|
|
|
|
99.70% |
| SM-324405 |
|
|
|
|
|
|
|
|
98.52% |
| SM-360320 |
|
|
|
|
|
|
|
|
99.41% |
| SM-360320 drug-linker |
|
|
|
|
|
|
|
|
|
| SMU-14a |
|
|
|
|
|
|
|
|
|
| SMU-C409 |
|
|
|
|
|
|
|
|
|
| SMU-C68 |
|
|
|
|
|
|
|
|
|
| SMU-CX1 |
|
|
|
|
|
|
|
|
99.9% |
| SMU-L11 |
|
|
|
|
|
|
|
|
99.64% |
| SMU-L11-R |
|
|
|
|
|
|
|
|
|
| SMU-R39 |
|
|
|
|
|
|
|
|
|
| SMU-Z1 |
|
|
|
|
|
|
|
|
|
| SMU127 |
|
|
|
|
|
|
|
|
|
| Sotirimod |
|
|
|
|
|
|
|
|
99.90% |
| Sparstolonin B |
|
|
|
|
|
|
|
|
99.94% |
| ssRNA40 sodium |
|
|
|
|
|
|
|
|
98.34% |
| ssRNA41 sodium |
|
|
|
|
|
|
|
|
97.51% |
| ssRNA42 sodium |
|
|
|
|
|
|
|
|
98.62% |
| Ste2Cys |
|
|
|
|
|
|
|
|
|
| Stepharine |
|
|
|
|
|
|
|
|
98.0% |
| Sulfo-ara-F-NMN |
|
|
|
|
|
|
|
|
99.18% |
| T5342126 |
|
|
|
|
|
|
|
|
98.1% |
| TAT-CIRP |
|
|
|
|
|
|
|
|
|
| Telratolimod |
|
|
|
|
|
|
|
|
98.44% |
| TH023 |
|
|
|
|
|
|
|
|
|
| TH1020 |
|
|
|
|
|
|
|
|
99.81% |
| TIC10g |
|
|
|
|
|
|
|
|
98.92% |
| Tilsotolimod |
|
|
|
|
|
|
|
|
99.46% |
| Tilsotolimod sodium |
|
|
|
|
|
|
|
|
|
| Tilsotolimod sodium scrambled negative control |
|
|
|
|
|
|
|
|
|
| TL8-506 |
|
|
|
|
|
|
|
|
95.0% |
| TL8-506 |
|
|
|
|
|
|
|
|
|
| TLR1 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
| Tlr1 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
| TLR2 agonist 1 |
|
|
|
|
|
|
|
|
|
| TLR2 antagonist-1 |
|
|
|
|
|
|
|
|
|
| TLR2 antagonist-2 |
|
|
|
|
|
|
|
|
|
| TLR2 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
| Tlr2 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
| Tlr2 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
| TLR2/1 agonist-1 |
|
|
|
|
|
|
|
|
|
| TLR2/9 antagonist 1 |
|
|
|
|
|
|
|
|
|
| TLR3 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
| Tlr3 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
| TLR4 agonist-1 |
|
|
|
|
|
|
|
|
|
| TLR4 agonist-1 TEA |
|
|
|
|
|
|
|
|
|
| TLR4 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
| Tlr4 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
| Tlr4 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
| TLR4-IN-1 |
|
|
|
|
|
|
|
|
|
| TLR4-IN-2 |
|
|
|
|
|
|
|
|
|
| TLR4-IN-C34 |
|
|
|
|
|
|
|
|
99.94% |
| TLR4-IN-C34 (Standard) |
|
|
|
|
|
|
|
|
|
| TLR4-IN-C34-C2-amide-C6-OH |
|
|
|
|
|
|
|
|
99.62% |
| TLR4-IN-C34-C2-COOH |
|
|
|
|
|
|
|
|
99.94% |
| TLR4/NF-κB-IN-1 |
|
|
|
|
|
|
|
|
99.92% |
| TLR4/NF-κB-IN-2 |
|
|
|
|
|
|
|
|
|
| TLR4/NF-κB/MAPK-IN-1 |
|
|
|
|
|
|
|
|
|
| TLR4L 10 |
|
|
|
|
|
|
|
|
|
| TLR6 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
| Tlr6 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
| Tlr6 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 1 |
|
|
|
|
|
|
|
|
98.19% |
| TLR7 agonist 14 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 15 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 16 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 17 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 18 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 19 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 2 |
|
|
|
|
|
|
|
|
98.80% |
| TLR7 agonist 20 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 20 hydrochloride |
|
|
|
|
|
|
|
|
99.86% |
| TLR7 agonist 21 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 22 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 23 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 24 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 26 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 27 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 28 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 29 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 3 |
|
|
|
|
|
|
|
|
99.90% |
| TLR7 agonist 30 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 31 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 32 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 33 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 4 |
|
|
|
|
|
|
|
|
98.87% |
| TLR7 agonist 5 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 6 |
|
|
|
|
|
|
|
|
98.08% |
| TLR7 agonist 7 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 8 |
|
|
|
|
|
|
|
|
|
| TLR7 agonist 9 |
|
|
|
|
|
|
|
|
|
| TLR7 antagonist-1 |
|
|
|
|
|
|
|
|
|
| TLR7-IN-1 |
|
|
|
|
|
|
|
|
|
| TLR7/8 agonist 1 |
|
|
|
|
|
|
|
|
98.42% |
| TLR7/8 agonist 1 dihydrochloride |
|
|
|
|
|
|
|
|
99.70% |
| TLR7/8 agonist 11 |
|
|
|
|
|
|
|
|
|
| TLR7/8 agonist 12 |
|
|
|
|
|
|
|
|
|
| TLR7/8 agonist 13 |
|
|
|
|
|
|
|
|
|
| TLR7/8 agonist 14 |
|
|
|
|
|
|
|
|
|
| TLR7/8 agonist 3 |
|
|
|
|
|
|
|
|
99.96% |
| TLR7/8 agonist 4 |
|
|
|
|
|
|
|
|
99.18% |
| TLR7/8 agonist 4 TFA |
|
|
|
|
|
|
|
|
|
| TLR7/8 agonist 6 |
|
|
|
|
|
|
|
|
98.93% |
| TLR7/8 agonist 7 |
|
|
|
|
|
|
|
|
|
| TLR7/8 agonist 8 |
|
|
|
|
|
|
|
|
98.69% |
| TLR7/8 agonist 9 |
|
|
|
|
|
|
|
|
|
| TLR7/8 antagonist 1 |
|
|
|
|
|
|
|
|
|
| TLR7/8 antagonist 2 |
|
|
|
|
|
|
|
|
99.68% |
| TLR7/8-IN-1 |
|
|
|
|
|
|
|
|
99.92% |
| TLR7/8/9 antagonist 2 |
|
|
|
|
|
|
|
|
98.96% |
| TLR7/8/9-IN-1 |
|
|
|
|
|
|
|
|
98.51% |
| TLR8 agonist 10 |
|
|
|
|
|
|
|
|
|
| TLR8 agonist 2 |
|
|
|
|
|
|
|
|
|
| TLR8 agonist 2 hydrochloride |
|
|
|
|
|
|
|
|
|
| TLR8 agonist 5 |
|
|
|
|
|
|
|
|
98.38% |
| TLR8 agonist 6 |
|
|
|
|
|
|
|
|
|
| TLR8 agonist 7 |
|
|
|
|
|
|
|
|
|
| TLR8 agonist 8 |
|
|
|
|
|
|
|
|
|
| TLR8 agonist 9 |
|
|
|
|
|
|
|
|
|
| TLR8 antagonist-1 |
|
|
|
|
|
|
|
|
99.95% |
| TLR8 antagonist-2 |
|
|
|
|
|
|
|
|
|
| TLR9 antagonist 1 |
|
|
|
|
|
|
|
|
|
| TLR9 antagonist 1 diformate |
|
|
|
|
|
|
|
|
|
| TLR9 antagonist 2 |
|
|
|
|
|
|
|
|
|
| TLR9 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
| Tlr9 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
| TLR9-IN-1 |
|
|
|
|
|
|
|
|
99.67% |
| TLR9-IN-2 |
|
|
|
|
|
|
|
|
|
| TMX-201 |
|
|
|
|
|
|
|
|
≥95.0% |
| Toll-like receptor modulator |
|
|
|
|
|
|
|
|
99.36% |
| Tomentosin |
|
|
|
|
|
|
|
|
98.95% |
| Tri(TLR4-IN-C34-C2-amide-C3-amide-PEG1)-amide-C3-COOH |
|
|
|
|
|
|
|
|
|
| Tri(TLR4-IN-C34-C2-amide-PEG1)-amide-C3-COOH |
|
|
|
|
|
|
|
|
|
| Tri(TLR4-IN-C34-PEG2-amide-PEG1)-amide-C3-COOH |
|
|
|
|
|
|
|
|
|
| TSI-13-48 |
|
|
|
|
|
|
|
|
|
| TSI-13-57 |
|
|
|
|
|
|
|
|
98.73% |
| TU-100 |
|
|
|
|
|
|
|
|
|
| UC-1V150 |
|
|
|
|
|
|
|
|
|
| UF010 |
|
|
|
|
|
|
|
|
99.83% |
| UM-3006 |
|
|
|
|
|
|
|
|
|
| VA06 |
|
|
|
|
|
|
|
|
|
| Vidutolimod |
|
|
|
|
|
|
|
|
93.85% |
| Vidutolimod sodium |
|
|
|
|
|
|
|
|
90.30% |
| WYJ-2 |
|
|
|
|
|
|
|
|
|
| Xanthine oxidase-IN-6 |
|
|
|
|
|
|
|
|
|
| Xelafaslatide |
|
|
|
|
|
|
|
|
99.88% |
| Zoratolimod |
|
|
|
|
|
|
|
|
|
| Zoratolimod scrambled negative control |
|
|
|
|
|
|
|
|
|
| α-Galactosyl FP20 sodium |
|
|
|
|
|
|
|
|
|
| α-Glucosyl FP20 sodium |
|
|
|
|
|
|
|
|
|
| α-Rhamnosyl FP20 sodium |
|
|
|
|
|
|
|
|
|
| β-D-Glucan |
|
|
|
|
|
|
|
|
99.00% |
| β-Funaltrexamine |
|
|
|
|
|
|
|
|
|
| β-Patchoulene |
|
|
|
|
|
|
|
|
|
| β-Funaltrexamine hydrochloride |
|
|
|
|
|
|
|
|
99.07% |
| D-Glucan |
|
|
|
|
|
|
|
|
96.0% |
| Tris(2-chloroethyl) phosphate |
|
|
|
|
|
|
|
|
97.07% |
| Tris(2-chloroethyl)phosphate-d12 |
|
|
|
|
|
|
|
|
99.15% |
| Sericin |
|
|
|
|
|
|
|
|
0% |
| Salvianolic acid D |
|
|
|
|
|
|
|
|
95.15% |
| Fosfructose |
|
|
|
|
|
|
|
|
98.0% |
| 2,4′-Dihydroxybenzophenone |
|
|
|
|
|
|
|
|
98.00% |
| Sodium Selenite |
|
|
|
|
|
|
|
|
99.00% |
| Human immunoglobulin E |
|
|
|
|
|
|
|
|
|
| Evolocumab |
|
|
|
|
|
|
|
|
98.4% |
| Grossamide |
|
|
|
|
|
|
|
|
98.0% |
| Robinin |
|
|
|
|
|
|
|
|
99.96% |
| Polyinosinic-polycytidylic acid potassium |
|
|
|
|
|
|
|
|
|
| Procyanidin B1 |
|
|
|
|
|
|
|
|
99.56% |
| Procyanidin B3 |
|
|
|
|
|
|
|
|
99.92% |
| Guluronic acid |
|
|
|
|
|
|
|
|
|
| Imiquimod |
|
|
|
|
|
|
|
|
99.96% |
| Imiquimod-d6 |
|
|
|
|
|
|
|
|
|
| Imiquimod-d7 |
|
|
|
|
|
|
|
|
|
| Imiquimod-d9 |
|
|
|
|
|
|
|
|
|
| Imiquimod maleate |
|
|
|
|
|
|
|
|
99.92% |
| Chloranil |
|
|
|
|
|
|
|
|
98% |
| Chitohexaose hexahydrochloride |
|
|
|
|
|
|
|
|
95.0% |
| Schaftoside |
|
|
|
|
|
|
|
|
99.70% |
| Physcion |
|
|
|
|
|
|
|
|
99.40% |
| Okanin |
|
|
|
|
|
|
|
|
99.98% |
| Complete Freund's adjuvant (CFA) |
|
|
|
|
|
|
|
|
|
| Alpinetin |
|
|
|
|
|
|
|
|
99.51% |
| Pamidronic acid |
|
|
|
|
|
|
|
|
99.05% |
| Pamidronate disodium |
|
|
|
|
|
|
|
|
98.0% |
| Pamidronate disodium pentahydrate |
|
|
|
|
|
|
|
|
98.0% |
| Isofraxidin |
|
|
|
|
|
|
|
|
99.94% |
| Isoacteoside |
|
|
|
|
|
|
|
|
99.73% |
| Tomaralimab |
|
|
|
|
|
|
|
|
99.42% |
| Ecliptasaponin A |
|
|
|
|
|
|
|
|
99.81% |
| Trimebutine |
|
|
|
|
|
|
|
|
99.42% |
| Trimebutine-d5 fumarate |
|
|
|
|
|
|
|
|
|
| Trimebutine-d3 hydrochloride |
|
|
|
|
|
|
|
|
|
| Corilagin |
|
|
|
|
|
|
|
|
99.96% |
| Raffinose |
|
|
|
|
|
|
|
|
98.0% |
| Teneligliptin hydrobromide hydrate |
|
|
|
|
|
|
|
|
99.97% |
| Chloroquine |
|
|
|
|
|
|
|
|
99.50% |
| Chloroquine-d5 |
|
|
|
|
|
|
|
|
99.90% |
| Saquinavir-d9 |
|
|
|
|
|
|
|
|
|
| Saquinavir |
|
|
|
|
|
|
|
|
99.77% |
| Saquinavir mesylate |
|
|
|
|
|
|
|
|
99.40% |
| Lard oil |
|
|
|
|
|
|
|
|
|
| Regaloside C |
|
|
|
|
|
|
|
|
99.62% |
| Phellopterin |
|
|
|
|
|
|
|
|
99.94% |
| Resiquimod-d5 |
|
|
|
|
|
|
|
|
98.33% |
| Resiquimod |
|
|
|
|
|
|
|
|
99.87% |
| Resatorvid |
|
|
|
|
|
|
|
|
98.31% |
| Polygalasaponin F |
|
|
|
|
|
|
|
|
99.85% |
| Methylprednisolone succinate |
|
|
|
|
|
|
|
|
99.67% |
| Byakangelicol |
|
|
|
|
|
|
|
|
98.66% |
| Atractylenolide I |
|
|
|
|
|
|
|
|
99.98% |
| Astringin |
|
|
|
|
|
|
|
|
98.97% |
| Imiquimod hydrochloride |
|
|
|
|
|
|
|
|
99.75% |
| Chloroquine dihydrochloride |
|
|
|
|
|
|
|
|
99.61% |
| Leonurine hydrochloride |
|
|
|
|
|
|
|
|
99.43% |
| Hydroxychloroquine-d4 sulfate |
|
|
|
|
|
|
|
|
|
| Hydroxychloroquine sulfate (Standard) |
|
|
|
|
|
|
|
|
99.96% |
| Hydroxychloroquine sulfate |
|
|
|
|
|
|
|
|
99.95% |
| Atazanavir sulfate |
|
|
|
|
|
|
|
|
99.68% |
| Chloroquine-d4 phosphate |
|
|
|
|
|
|
|
|
|
| Chloroquine-d5 diphosphate |
|
|
|
|
|
|
|
|
|
| Chloroquine phosphate |
|
|
|
|
|
|
|
|
99.89% |
| Fosfenopril |
|
|
|
|
|
|
|
|
99.85% |
| Fosfenopril-d7 |
|
|
|
|
|
|
|
|
|
| Chymotrypsin, Human Pancreas |
|
|
|
|
|
|
|
|
|
| Nalmefene-d4 |
|
|
|
|
|
|
|
|
|
| Gypenoside XLIX |
|
|
|
|
|
|
|
|
99.88% |
| Vesatolimod |
|
|
|
|
|
|
|
|
99.90% |
| Thiamine hydrochloride |
|
|
|
|
|
|
|
|
99.97% |
| Mogroside III-E |
|
|
|
|
|
|
|
|
99.30% |
| Phytolacca americana Lectin |
|
|
|
|
|
|
|
|
|
| Hydroxychloroquine-d4-1 sulfate |
|
|
|
|
|
|
|
|
|
| Hydroxychloroquine-d5 |
|
|
|
|
|
|
|
|
|
| Hydroxychloroquine |
|
|
|
|
|
|
|
|
99.82% |
| Hydroxychloroquine Impurity E |
|
|
|
|
|
|
|
|
99.83% |
| 4-[(7-Chloro-4-quinolinyl)amino]-1-pentanol-d4 |
|
|
|
|
|
|
|
|
|
| Cholesterol oxidase, rhodococcus sp |
|
|
|
|
|
|
|
|
|
| Chymotrypsin (MS grade) |
|
|
|
|
|
|
|
|
|
| Chymotrypsin |
|
|
|
|
|
|
|
|
|
| Lipopolysaccharides, from S. enterica serotype minnesota Re 595 (Re mutant) |
|
|
|
|
|
|
|
|
|
| Lipopolysaccharides, from E. coli K-235 |
|
|
|
|
|
|
|
|
|
| Lipopolysaccharides, from E. coli O111:B4 |
|
|
|
|
|
|
|
|
|
| Lipopolysaccharides, from E. coli O127:B8 |
|
|
|
|
|
|
|
|
|
| Lipopolysaccharides, from E. coli O128:B12 |
|
|
|
|
|
|
|
|
|
| Lipopolysaccharides, from E. coli O26:B6 |
|
|
|
|
|
|
|
|
|
| Lipopolysaccharides, from E. coli O55:B5 |
|
|
|
|
|
|
|
|
|
| Lipopolysaccharides, from Proteus mirabilis |
|
|
|
|
|
|
|
|
|
| Lipopolysaccharides, from Proteus vulgaris |
|
|
|
|
|
|
|
|
|
| Lipopolysaccharides, from P. gingivalis |
|
|
|
|
|
|
|
|
|
| Lipopolysaccharides, from S. marcescens |
|
|
|
|
|
|
|
|
|
| Lipopolysaccharides, from S. enterica serotype enteritidis |
|
|
|
|
|
|
|
|
|
| Lipopolysaccharides, from S. enterica serotype typhimurium |
|
|
|
|
|
|
|
|
|
| Lipopolysaccharides, from S. enterica serotype abortus equi |
|
|
|
|
|
|
|
|
|
| Lipopolysaccharides, from Klebsiella pneumoniae |
|
|
|
|
|
|
|
|
|
| Lipopolysaccharides, from P. aeruginosa 10 |
|
|
|
|
|
|
|
|
|
| Atractyloside A |
|
|
|
|
|
|
|
|
98.11% |
| Benzoylaconine |
|
|
|
|
|
|
|
|
99.92% |
| Benzyl alcohol |
|
|
|
|
|
|
|
|
99.99% |
| Zinc Gluconate |
|
|
|
|
|
|
|
|
98.0% |
| Dracorhodin perchlorate |
|
|
|
|
|
|
|
|
99.02% |
| Zymosan (ZM), 95% |
|
|
|
|
|
|
|
|
96.11% |
| Zymosan A |
|
|
|
|
|
|
|
|
82.2% |
| Rotundic acid |
|
|
|
|
|
|
|
|
98.41% |
| Atazanavir |
|
|
|
|
|
|
|
|
99.12% |
| Atazanavir-d24 |
|
|
|
|
|
|
|
|
|
| Atibuclimab |
|
|
|
|
|
|
|
|
≥99.0% |
| Arjunolic acid |
|
|
|
|
|
|
|
|
98.17% |
| Trimebutine maleate |
|
|
|
|
|
|
|
|
99.66% |